Find Nina Patrick here: https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine energy span as a fatigue biomarker, GSK's $950M 35 Pharma acquisition, January AI's Medicare app entry, OsteoBoost's $8M funding, Seragon's SRN-901 33% mouse lifespan boost, and skin longevity advances.

• Energy span proposes viewing fatigue as an early mitochondrial decline signal before chronic disease. Advances in wearable technology and continuous monitoring are making it possible to track proxies of energy regulation – heart rate variability as a marker of autonomic balance, glucose dynamics as a reflection of metabolic stability, sleep architecture as a proxy for recovery.
• GSK acquired 35Pharma for $950M, gaining a pulmonary hypertension candidate affecting lung arteries. Proof-of-concept trials are expected to begin soon in two forms of the disease: pulmonary arterial hypertension (PAH) and PH linked to heart failure with preserved ejection fraction (PH-HFpEF).
• January AI joined Medicare's app library for 69M users, using food photos and AI to predict glucose responses. It lowers barriers for metabolic coaching but needs integration and targeting for adoption.
• OsteoBoost raised $8M for a vibration wearable mimicking bone-loading to combat osteoporosis in 200M worldwide. It offers non-drug options amid bisphosphonate trade-offs, with mixed prior studies on dose.
• Seragon's oral SRN-901 extended late-life mouse lifespan 33%, cut frailty 70%, tumors 30% via mitophagy and NAD support, outperforming rapamycin.
• Epicutis' TCP serum improved skin appearance 77% in 8-week trial versus placebo, signaling cellular modulation in aesthetics.

----------

Hosts:Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

News & References:

• GSK acquires 35Pharma in $950m deal, advancing PH drug → https://longevity.technology/news/gsk-acquires-35pharma-in-950m-deal-advancing-ph-drug/
• Energy Span reframes fatigue as early warning → https://longevity.technology/news/energy-span-reframes-fatigue-as-early-warning/
• Osteoboost raises $8m to scale bone wearable → https://longevity.technology/news/osteoboost-raises-8m-to-scale-bone-wearable/
• January AI enters Medicare App Library, reaches 69m+ patients → https://longevity.technology/news/january-ai-enters-medicare-app-library-reaches-69m-patients/
• Seragon study shows SRN-901 extends median lifespan in mice → https://longevity.technology/news/seragon-study-shows-srn-901-extends-median-lifespan-in-mice/
• Epicutis clinical study shows 77% improvement in skin appearance → https://longevity.technology/news/epicutis-clinical-study-shows-77-improvement-in-skin-appearance/